Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 10 (October)

1. The practice of Scottish urologists in the assessment and management of fracture risk in the ageing male being treated for prostate cancer.
   ScientificWorldJournal, 7: 1590-5. [Abstract] [Full-text]
2. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
   Int J Cancer, 121(10): 2212-7. [Abstract] [Full-text]
3. Modulating metastasis by a lymphangiogenic switch in prostate cancer.
   Int J Cancer, 121(10): 2153-61. [Abstract] [Full-text]
4. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
   Cancer Res, 67(19): 9535-41. [Abstract] [Full-text]
5. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.
   Cancer Res, 67(19): 9425-34. [Abstract] [Full-text]
6. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
   Cancer Res, 67(19): 9417-24. [Abstract] [Full-text]
7. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
   Cancer Res, 67(19): 9371-9. [Abstract] [Full-text]
8. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation.
   Cancer Res, 67(19): 9294-303. [Abstract] [Full-text]
9. Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.
   Cancer Res, 67(19): 9258-65. [Abstract] [Full-text]
10. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis.
    Cancer Res, 67(19): 9199-206. [Abstract] [Full-text]
11. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.
    Cancer Res, 67(19): 9089-96. [Abstract] [Full-text]
12. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.
    Cancer Res, 67(19): 9001-5. [Abstract] [Full-text]
13. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.
    J Natl Cancer Inst, 99(19): 1484-9. [Abstract] [Full-text]
14. Physical function in men with prostate cancer on androgen deprivation therapy.
    Phys Ther, 87(10): 1325-33. [Abstract] [Full-text]
15. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
    Cancer Immunol Immunother, 56(12): 1921-30. [Abstract] [Full-text]
16. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Cancer Chemother Pharmacol, 61(1): 53-61. [Abstract] [Full-text]
17. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
    JAMA, 298(13): 1533-8. [Abstract] [Full-text]
18. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.
    Br J Cancer, 97(7): 952-6. [Abstract] [Full-text]
19. Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells.
    Br J Cancer, 97(7): 941-8. [Abstract] [Full-text]
20. Prostate high dose rate brachytherapy in a free-standing cancer center setting.
    Am J Clin Oncol, 30(5): 520-5. [Abstract] [Full-text]
21. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Prostate, 67(14): 1590-9. [Abstract] [Full-text]
22. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Prostate, 67(14): 1543-9. [Abstract] [Full-text]
23. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection.
    Prostate, 67(14): 1537-42. [Abstract] [Full-text]
24. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
    Prostate, 67(14): 1576-89. [Abstract] [Full-text]
25. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.
    Prostate, 67(14): 1565-75. [Abstract] [Full-text]
26. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Prostate, 67(14): 1550-64. [Abstract] [Full-text]
27. HIF-1alpha promotes survival of prostate cells at a high zinc environment.
    Prostate, 67(14): 1514-23. [Abstract] [Full-text]
28. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
    Prostate, 67(14): 1507-13. [Abstract] [Full-text]
29. Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer.
    Prostate, 67(14): 1524-36. [Abstract] [Full-text]
30. Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
    Prostate, 67(14): 1487-97. [Abstract] [Full-text]
31. S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death.
    Prostate, 67(14): 1498-506. [Abstract] [Full-text]
32. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer.
    Mol Immunol, 45(3): 839-48. [Abstract] [Full-text]
33. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer.
    Eur J Cancer Prev, 16(5): 415-21. [Abstract] [Full-text]
34. Short- and long-term mortality with localized prostate cancer.
    Arch Intern Med, 167(18): 1944-50. [Abstract] [Full-text]
35. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    Cancer, 110(8): 1723-8. [Abstract] [Full-text]
36. Treatment outcomes of small cell carcinoma of the prostate: a single-center study.
    Cancer, 110(8): 1729-37. [Abstract] [Full-text]
37. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
    Cancer, 110(8): 1708-14. [Abstract] [Full-text]
38. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Cell Signal, 19(12): 2487-97. [Abstract] [Full-text]
39. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
    J Urol, 178(5): 2176-80. [Abstract] [Full-text]
40. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    J Urol, 178(5): 1974-9; discussion 1979. [Abstract] [Full-text]
41. Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
    J Urol, 178(5): 1846-54. [Abstract] [Full-text]
42. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    J Urol, 178(5): 1920-4; discussion 1924. [Abstract] [Full-text]
43. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    J Urol, 178(5): 1925-8. [Abstract] [Full-text]
44. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.
    J Urol, 178(5): 1929-32; discussion 1932. [Abstract] [Full-text]
45. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    J Urol, 178(5): 1933-7; discussion 1937-8. [Abstract] [Full-text]
46. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men.
    J Urol, 178(5): 1939-44; discussion 1945. [Abstract] [Full-text]
47. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    J Urol, 178(5): 1946-51; discussion 1951. [Abstract] [Full-text]
48. Applying population dynamics modeling to patients with lymph node positive prostate cancer.
    J Urol, 178(5): 1952-5; discussion 1955-6. [Abstract] [Full-text]
49. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    J Urol, 178(5): 1957-62; discussion 1962. [Abstract] [Full-text]
50. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
    J Urol, 178(5): 1963-7. [Abstract] [Full-text]
51. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    J Urol, 178(5): 1968-73; discussion 1973. [Abstract] [Full-text]
52. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    J Natl Cancer Inst, 99(20): 1516-24. [Abstract] [Full-text]
53. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
    J Natl Cancer Inst, 99(20): 1525-33. [Abstract] [Full-text]
54. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
    J Natl Cancer Inst, 99(20): 1510-5. [Abstract] [Full-text]
55. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer.
    Expert Opin Biol Ther, 7(11): 1723-30. [Abstract] [Full-text]
56. A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours.
    Cancer Lett, 258(1): 126-34. [Abstract] [Full-text]
57. Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells.
    Cancer Lett, 258(1): 70-9. [Abstract] [Full-text]
58. Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer.
    Int J Radiat Oncol Biol Phys, 69(4): 1110-6. [Abstract] [Full-text]
59. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
    Int J Radiat Oncol Biol Phys, 69(4): 1100-9. [Abstract] [Full-text]
60. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 69(4): 1090-9. [Abstract] [Full-text]
61. Analytic investigation into effect of population heterogeneity on parameter ratio estimates.
    Int J Radiat Oncol Biol Phys, 69(4): 1323-30. [Abstract] [Full-text]
62. 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy.
    Int J Radiat Oncol Biol Phys, 69(4): 1074-83. [Abstract] [Full-text]
63. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
    Int J Radiat Oncol Biol Phys, 69(4): 1117-23. [Abstract] [Full-text]
64. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
    Int J Radiat Oncol Biol Phys, 69(4): 1084-9. [Abstract] [Full-text]
65. Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data.
    Expert Opin Investig Drugs, 16(11): 1841-9. [Abstract] [Full-text]
66. Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian king from Arzhan (Siberia, Russia).
    Int J Cancer, 121(12): 2591-5. [Abstract] [Full-text]
67. Acne and risk of prostate cancer.
    Int J Cancer, 121(12): 2688-92. [Abstract] [Full-text]
68. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers.
    Int J Cancer, 121(12): 2748-52. [Abstract] [Full-text]
69. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
    Int J Cancer, 121(12): 2596-605. [Abstract] [Full-text]
70. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
    Int J Cancer, 121(12): 2661-7. [Abstract] [Full-text]
71. ANXA7 expression represents hormone-relevant tumor suppression in different cancers.
    Int J Cancer, 121(12): 2628-36. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.